Sangamo Therapeutics Inc.
SGMO
NGS
Sector: Healthcare
Industry: Biotechnology
6.33
USD
0.51
(8.76%)
Optionable: Yes Market Cap: 820 M 90-day average vol: 1,765,205
Previous close: 5.82 Open: 5.85 Bid: 6.28 Ask: 6.28
52 week range
3.12 11.49
Last updated: Sunday 14th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Returns
7 Day Return | 19.66% | |
1 Month Return | 39.43% | |
3 Month Return | 63.14% | |
1 Year Return | -37.01% | |
3 Year Return | -45.24% | |
5 Year Return | -45.43% | |
YTD Return | -15.60% |
Risk
Custom Beta One Year | 1.72 |
Custom Beta Three Years | 1.23 |
Beneish M Score | -1.84 |
Altman Z Score | -0.95 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 79.98 |
14 Day SMA ($) | 4.98 |
14 Day EMA ($) | 5.21 |
Money Flow Index | 55.87 |
Average True Range | 0.34 |
50 Day SMA ($) | 4.40 |
200 Day SMA ($) | 5.90 |
ADX | 13.63 |
MACD | 0.39 |
Growth
Free Cash Flow QoQ Growth | 11.23% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 15.38% |
Revenue QoQ Growth | 0.88% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Yahoo Finance 2/28/2022
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 2/24/2022
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
Yahoo Finance 2/24/2022
Sangamo Therapeutics rises 5% after hours following Q4 earnings
Seeking Alpha 2/24/2022
Sangamo Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Seeking Alpha 2/24/2022
Sangamo Therapeutics GAAP EPS of -$0.26 beats by $0.09, revenue of $28M beats by $0.64M
Seeking Alpha 2/24/2022
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Yahoo Finance 2/24/2022
Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Seeking Alpha 2/24/2022
Sangamo Therapeutics Q4 2021 Earnings Preview
Seeking Alpha 2/23/2022
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
Yahoo Finance 2/17/2022
Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Yahoo Finance 2/8/2022
Sangamo's gene therapy for Fabry Disease shows safety in interim phase 1/2 trial data
Seeking Alpha 2/8/2022
Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial
Yahoo Finance 2/8/2022
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
Yahoo Finance 2/7/2022
Sangamo Therapeutics (SGMO) Investor Presentation - Slideshow
Seeking Alpha 2/3/2022
PrairieView Partners, LLC Buys iShares Short-Term National Muni Bond ETF, Avantis Core ...
Yahoo Finance 1/21/2022
McGuire Investment Group, LLC Buys SPDR Bloomberg 1-3 Month T-Bill ETF, WisdomTree Floating ...
Yahoo Finance 1/13/2022
Sanofi terminates collaboration with Sangamo for sickle cell disease program
Seeking Alpha 1/6/2022
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
Yahoo Finance 1/6/2022
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
Yahoo Finance 1/4/2022
BioMarin settles trade secrets 'misunderstanding' with former employee
Yahoo Finance 12/20/2021
Pfizer (PFE) Gets Approval for New Eczema Drug in Europe
Yahoo Finance 12/13/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 47.848
Financials
SGMO Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 22 M | 24 M | 46 M | 40 M | 19 M | 37 M | 84 M | 102 M | 118 M | 111 M |
| Cost of sales | -2 M | -1 M | -2 M | -2 M | -1 M | -825000 | 3 M | -5 M | -13 M | -20 M |
| Gross operating profit | 22 M | 24 M | 46 M | 40 M | 19 M | 37 M | 84 M | 102 M | 118 M | 111 M |
| Selling Gen & administrative expense | 12 M | 14 M | 16 M | 19 M | 26 M | 27 M | 47 M | 62 M | 67 M | 63 M |
| Research & development expense | 32 M | 37 M | 57 M | 67 M | 66 M | 66 M | 115 M | 146 M | 181 M | 231 M |
| Operating income | -22 M | -27 M | -27 M | -47 M | -73 M | -56 M | -77 M | -105 M | -130 M | -183 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -66000 | 82000 | 364000 | 431000 | 887000 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income (EBT) | -22 M | -27 M | -26 M | -46 M | -72 M | -55 M | -69 M | -95 M | -121 M | -178 M |
| Income taxes | 0 | 0 | 0 | -6 M | -14000 | 0 | 0 | 0 | 345000 | 306000 |
| Net income from total operations | -22 M | -27 M | -26 M | -41 M | -72 M | -55 M | -69 M | -95 M | -121 M | -178 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -22 M | -27 M | -26 M | -41 M | -72 M | -55 M | -68 M | -95 M | -121 M | -178 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -22 M | -27 M | -26 M | -41 M | -72 M | -55 M | -69 M | -95 M | -121 M | -178 M |
| Depreciation | 2 M | 1 M | 2 M | 2 M | 1 M | 825000 | -3 M | 5 M | 13 M | 20 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -22 M | -26 M | -26 M | -46 M | -72 M | -55 M | -75 M | -96 M | -116 M | -166 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -0.42 | -0.48 | -0.39 | -0.58 | -1.02 | -0.7 | -0.7 | -0.85 | -0.9 | -1.23 |
| Diluted EPS total | -0.42 | -0.48 | -0.39 | -0.58 | -1.02 | -0.7 | -0.7 | -0.85 | -0.9 | -1.23 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!